p://www.varianinc.com/products/
Varian, Inc. is a leading worldwide supplier of scientific instruments
and vacuum technologies for life science and industrial applications. The
company provides complete solutions, including instruments, vacuum
products, laboratory consumable supplies, software, training and support
through its global distribution and support systems. Varian, Inc. employs
approximately 4,000 people worldwide and operates manufacturing facilities
in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year
2007 sales of $921 million, and its common stock is traded on the NASDAQ
Global Select Market under the symbol, "VARI." Further information is
available on the company's Web site: http://www.varianinc.com.
For More Information, Contact:
Public Relations
Varian, Inc.
650.424.3845
pr@varianinc.com
'/>"/>SOURCE Varian, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine technology :1.
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products2.
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin3.
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel4.
New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy5.
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-21686.
Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy7.
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients8.
Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting9.
Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation10.
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation11.
Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss